Sandra Muñoz López

Reumatóloga. Centro Médico Nacional 20 de noviembre. Especialista en métodos de investigación

[Kazuo Matsui @kazuomatsui]

#EULAR2026 Abstract Plenary: OP002 ANISE-II: シェーグレン病患者におけるAnifrolumab Phase2試験
SjD患者55-80%でType I IFNシグニチャ、抗SSA/Roと関連. 24週CRESS反応性は、ANI 80% vs PBO 30%. ESSPRIでは、乾燥症状、倦怠感が最も大きく改善．副作用は軽度の感染症が中心で、安全性は良好．耳下腺生検で、腺房でのMxA発現低下を認めた．今後は大規模試験で有効性と安全性を確認する必要がある．
https://t.co/9UgQUOKXjh
#SjD #Anifrolumab

[Roxana González @RoxOsler]

Tratamientos para nefritis lúpica:
🔹 Belimumab actúa sobre BAFF/supervivencia B
🔹Voclosporina combina inhibición de calcineurina y estabilización podocitaria
🔹Obinutuzumab ofrece depleción B anti-CD20 más profunda. #Jornadanefroreuma

[Soc.Esp.Reumatología @SEReumatologia]

🤰🏻“El embarazo es posible en mujeres con enfermedades reumáticas autoinmunes sistémicas, pero hay que planificarlo para minimizar cualquier riesgo. Es fundamental la evaluación pre-concepcional y un equipo multidisciplinar. A día de hoy hay medicación compatible y esto es importante explicarlo a las pacientes”, Dra. @BMagallares, de @reuma_santpau

[Roxana González @RoxOsler]

La selección terapéutica en nefritis lúpica debe integrar mecanismo de acción, histología, proteinuria, eGFR, serología, actividad extrarrenal, seguridad y acceso.
Se necesitan marcos de decisión basados en perfiles clínico-biológicos. #Jornadanefroreuma

[JAMA Internal Medicine @JAMAInternalMed]

#Arthritis is a leading cause of pain and disability that affects nearly one-third of older US adults, many have inflammatory arthritis.

💡 This Clinical Insights discusses inflammatory arthritis in older adults and offers practical guidance. https://t.co/VknqhVWdRL

[Nelly ZIADE 🍀 @Nellziade]

🔎 Can US predict PsA progression from psoriasis?

YES: synovio-entheseal inflammation predicts progression in 183pts prospective cohort

#OP0183 #EULAR2026 @RheumNow

[Eric Topol @EricTopol]

In today's @TheLancet there are 3 papers on cardiometabolic disease: biology, epidemiology, prevention/treatment.
The sobering and all to common story from womb to tomb conveyed in this graphic
https://t.co/rVs2Yz97NC
https://t.co/OpuJTia0bC
https://t.co/i714onXoCG

[Prakashini @prakashini_]

Back to basics at #EULAR26
#SpA

[Henry C Fung| MM, lymphoma, leukemia & CART @HenrychihangFu1]

For 100 years we classified disease by organ.

Perhaps the next era will classify disease by immune ecosystem.

What if CAD, APS, lupus, obesity, MGUS, and myeloma are not completely separate diseases?

Different organs.
Different specialists.
Different textbooks.

Yet many share:

🧬 B-cell activation
🧬 Plasma cells
🧬 Autoantibodies
🧬 Chronic inflammation
🧬 Immune aging
🧬 Senescence

The therapeutic ladder is already emerging:

CD20 → CD19 → CD38 → BCMA → CAR-T

Are we treating different diseases…

or different manifestations of a dysregulated immune ecosystem?

Not a conclusion.

Not medical advice.

Just a hypothesis connecting observations across cardiology, rheumatology, immunology, hematology, oncology, and aging biology.

In biology we trust. 🧬

👇 More to see in the figure.

#Immunology #MultipleMyeloma #CAR-T #Autoimmunity #APS #MGUS #CardioOncology #Aging

[David Liew @drdavidliew]

Which biologic works best in psoriasis?

BE-BOLD at #EULAR2026 is the first IL-17A/F vs IL-23p19 head-to-head (bim vs ris), and it's in PsA.

but so many H2H in psoriasis!
I wanted to compile them, so I asked ChatGPT to put a table together, and it seems to check out:
@RheumNow

[Dr. John Cush @RheumNow]

The pain that inflammation does not explain in SpA and PsA

At EULAR 2026, the NEUPIA study (OP0317), a prospective observational investigation conducted at KU Leuven and University Hospitals Leuven, provides the most detailed longitudinal characterisation to date of these non-inflammatory pain phenotypes in PsA, SpA, and RA, and their associations with anxiety, depression, and sleep disturbance over six months.

https://t.co/6PlcepgLQp

[Scholarship for PhD @ScholarshipfPhd]

Writing a Scientific Article: A step-by-step guide for beginners

[Lupus Europe @LupusEurope]

Our Swiss Knife Survey found that fatigue affected 84.9% of respondents and was reported as the symptom least taken into account in treatment plans.

Read the study: https://t.co/QOCI5TsVyX

#EULAR2026

[mariajosem @mariaj_morenom]

#EULAR2026 Acordaros de la guía para cuidado de úlceras digitales en Esclerodermia que es libre
👉 https://t.co/2xpPxyl95C
@AEEsclerodermia @SEReumatologia @SMurcianaReuma

[Nelly ZIADE 🍀 @Nellziade]

🏠 Take Home Messages from the early #axSpA session

🔺 Earlier diagnosis is possible and better
🔺 Early axSpA is not synonymous to mild
🔺 Longitudinally, early axSpA is heterogeneous
🔺 MRI has transformed the field
❗️Beware of pitfalls

#EULAR2026 @RheumNow

[Ernesto Cairoli @ErnestoCairoli]

VACUNAS en pacientes con enfermedades autoinmunes.
Actualización EULAR 2026.

[Aravind Palraj @Rheumat_Aravind]

🧪 RF vs Anti-CCP

🚨 Positive RF ≠ RA

🚨 Anti-CCP is more specific than RF

🚨 Anti-CCP may precede clinical RA

🚨 RF + Anti-CCP positivity predicts more erosive disease

🚬 Smoking is strongly linked to Anti-CCP–positive RA

#RheumatoidArthritis #AntiCCP @IhabFathiSulima @docakx #Rheumatology #MedTwitter #MedicalEducation

[Oscar Arias @OACerebro]

Enjoy!

https://t.co/YybiZJvXP8

[Intersticiales INER @INERsticio]

Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment—an expert group consensus statement - The Lancet Respiratory Medicine https://t.co/JA8Dw06qxr
@jorroser

[Rheuma Doc @LastManStand85]

EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome [2025]
✅ Definite total score >5.5 + atleast 1 clinical domain + anti-ARS ab mandatory
❓Probable >5 + atleast 1 clinical domian, anti-ARS ab not mandatory
#Rheumatology #MedTwitter